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Abstract
Background Papillary microcarcinoma (PMC) is increas-
ing in incidence because of diagnosis by ultrasound-guided
ﬁne-needle aspiration cytology.
Methods Between January 1966 and December 1995, we
treated 6019 patients with papillary cancer; among them,
2070 patients with PMC were studied.
Results PMC is essentially very similar to papillary
cancer that is 11 mm or larger and has a very good prog-
nosis. Smaller tumors and younger patients have a better
prognosis. Among PMC, larger tumors (6–10 mm) recur in
14% at 35 years compared with 3.3% in patients with
smaller tumors. Patients older than 55 years have recur-
rence in 40% at 30 years, with a worse prognosis than
younger patients who have a recurrence rate of less than
10%. Extracapsular invasion by the primary tumor also has
a higher recurrence rate. The majority of recurrences are in
the neck. Therefore, annual ultrasound of the neck is
effective for recurrence surveillance.
Conclusion Papillary microcarcinoma is similar to larger
papillary carcinomas with tumor characteristics and age-
based recurrence rate that extends for many years, justi-
fying long surveillance after surgery.
Introduction
Papillary microcarcinoma (PMC), which is deﬁned as
papillary carcinoma of the thyroid that is less than 10 mm
in diameter, is diagnosed with increasing frequency
recently due to the extensive use of ultrasound-guided ﬁne-
needle aspiration cytology. However, there is no consensus
in the management of the disease, resulting in a wide
spectrum of responses for this condition ranging from
observation without treatment [1] to total thyroidectomy
plus radioactive iodine treatment [2, 3]. These extreme
differences may partly be the product of the lack of epi-
demiologic data about this condition. At the Noguchi
Thyroid Clinic and Hospital Foundation, we have been
gathering follow-up data on thyroid patients since 1922 and
currently perform over 1500 thyroid operations annually.
Also, according to Fukunaga and Yatani [4], the incidence
of occult thyroid carcinoma is signiﬁcantly higher in Japan
(28.4%) and in the Hawaiian Japanese population (24.2%)
when compared with the populations of Canada (6%),
Poland (9.1%), and Columbia (5.6%). Here we present our
experience with PMC, including a long follow-up period,
so that it might help others understand of the nature of this
condition.
Patients and methods
Between January 1966 and December 1995, 6019 patients
with papillary thyroid cancer were operated on at our
institution. Among them, 371 underwent nonradical sur-
gery; because the precise extent of the tumor was not
measurable, they were excluded from this study. Those
who concomitantly had other types of malignancies and
patients whose operation method or other important
information was lacking were also excluded. Of the
remaining 4840 patients, 2070 (42.8%) had PMC.
Although multiple autopsy studies have stated that the
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male-to-female ratio in our sample was 1:8.9 [4].
The age at the time of operation ranged from 11 to 83
years old and the distribution conformed well to a sym-
metric bell curve around the median age of 47.
Hashimoto’s disease was concomitantly seen in 188
patients (9.1%) and Graves’ disease was concomitant in
824 patients (39.8%). Single-variable recurrence-free sur-
vival rates were calculated using the Kaplan-Meier method
and multivariate risk factors were calculated using Cox’s
regression hazard model.
Results
Age
The patient’s age at initial surgery was one of the sig-
niﬁcant risk factors inﬂuencing recurrence-free survival by
single-variable analysis (Fig. 1). However, age was not a
risk factor for recurrence of the disease by Cox’s pro-
portional hazard model (Table 1). One explanation for this
apparent contradiction is that patients who were operated
on when they were 56 years old or older would be 81
years old or older after 25 years of follow-up. Therefore, a
large number of patients might have died from causes
other than PMC. As the population diminishes, the relative
weight of a single recurrence is increased, thus contrib-
uting to a signiﬁcant decrease in recurrence-free survival
ratio.
Size of primary tumor
A primary tumor 1-5 mm in diameter was seen in 1234
patients. The remaining 836 patients had a maximum pri-
mary tumor diameter of 6-10 mm. The 1-5-mm tumor
group had an improved recurrence-free survival rate 35
years after primary surgery (Fig. 2).
Autoimmunity
PMC in the presence of autoimmune thyroid diseases
showed improved recurrence-free survival 35 years after
primary surgery (Fig. 3). The ratio of Hashimoto’s thy-
roiditis to Graves’ disease was 1:4.4.
Preoperative diagnosis
When preoperative diagnosis was a benign nodule, the
prognosis was slightly better than when preoperative
diagnosis was a malignant nodule (Fig. 4). Comparing the
preoperative diagnosis regardless of both tumor size and
nodal metastasis, patients with Hashimoto’s disease or
Graves’ disease had a better prognosis (Fig. 4).
s r a e Y   p u - w o l l o F
R
e
c
u
r
r
e
n
t
-
f
r
e
e
 
S
u
r
v
i
v
a
l
6 4 0 . 0 < p     k n a R - g o L
d l o   s r a e y   5 2   n a h t   s s e L
d l o   s r a e y   5 5 - 6 2
d l o   s r a e y   6 5   n a h t   e r o M
0 4 0 3 0 2 0 1 0
5 . 0
6 . 0
7 . 0
8 . 0
9 . 0
0 . 1
Fig. 1 Recurrence-free survival rates versus patient age between
1966 and 1995. Age was a signiﬁcant factor in recurrence-free
survival by single-variable analysis
Table 1 Cox’s proportional hazard model
Autoimmunity p\0.0000
Gross nodal metastases p\0.0043
Maximum dimension p\0.0043
Adhesion to esophagus p\0.0314
Gender p\0.1388
Age at surgery p\0.5094
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Fig. 2 Recurrence-free survival rates by size of tumor. Tumors up to
5 mm showed signiﬁcantly better recurrence-free survival rates 35
years after surgery than tumors between 6 and 10 mm
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Fig. 3 Recurrence-free survival rates of patients with autoimmunity.
Patients with autoimmune thyroid diseases such as Graves’ disease
and Hashimoto’s disease had signiﬁcantly better prognosis 35 years
after surgery than patients without an autoimmune disease
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123Adhesion
When the primary tumor had adhered to the recurrent
nerve, the recurrence rate of PMC was substantially higher
(Fig. 5). Adhesion to the esophagus affected recurrence-
free survival more substantially the with recurrence-free
survival rate down to 60.5% (Fig. 6). Adhesion to the
recurrent nerve did not signiﬁcantly affect recurrence by
Cox’s proportional hazard model, whereas adhesion to the
esophagus did.
Nodal metastasis
There was no signiﬁcant difference between cases in which
gross lymph node metastases were not found and cases in
which lymph node metastases were not searched for.
However, those who had gross nodal metastases showed a
moderately lower recurrence-free survival (Fig. 7). The
number of grossly involved lymph nodes was inversely
related to recurrence-free survival (Fig. 8), excluding the
group in whom the nodal status was not described. This
group had recurrence-free survival numbers that were
similar to the group with no involved lymph nodes (Fig. 7).
Of the 246 patients who underwent modiﬁed radical neck
dissection, metastasis was absent in only 1. The median
number of metastatic nodes was 2, and the range was 1-43
nodes. Of the 255 patients who underwent central com-
partment node excision, metastasis was absent in 136
patients (53.3%). Fifty-eight patients (42.6%) had one
metastatic lymph node and 19 patients (14.0%) had two
metastatic lymph nodes. The remaining patients had up to
14 metastatic nodes (mean = 1.1 ± 2.0).
Other risk factors
This study revealed no signiﬁcant differences in recur-
rence-free survival by gender. A benign preoperative
diagnosis predicted a slightly better recurrence-free prog-
nosis; however, this difference was small.
Timing of recurrence and sites
The maximum interval between primary surgery and the
ﬁrst recurrence was 31 years (Figs. 9 and 10). There were
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Fig. 4 Recurrence-free survival rates of patients with preoperative
diagnosis. Patients preoperatively diagnosed with benign nodules had
signiﬁcantly better prognosis 35 years after surgery than patients
preoperatively diagnosed with malignant tumors. Patients whose
tumors were not preoperatively identiﬁed had the best prognosis
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Fig. 5 Recurrence-free survival rates of patients with primary tumor
adherent to the recurrent nerve. Patients with documented invasion to
the recurrent nerve had signiﬁcantly worse recurrence-free survival
than patients with no documented invasion to the recurrent nerve
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Fig. 6 Recurrence-free survival rates of patients with primary tumor
adherent to the esophagus. Patients with documented invasion of the
esophagus had signiﬁcantly worse recurrence-free survival than
patients with no documented invasion of the esophagus
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Fig. 7 Patients with documented gross nodal metastases had signif-
icantly worse recurrence-free survival than patients with no
documented gross nodal metastases
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12373 patients who experienced recurrence. Median of the
interval was 10.29 years and standard deviation was
10.8 ± 6.51 years. Second recurrences were seen in 12
patients. One of them had the ﬁrst recurrence at 0.7 year
and the site was contralateral lymph nodes. The second
recurrence was in the lungs years after primary surgery and
a few weeks after recurrent surgery. This case taught us
that careful preoperative work-up is important even with
PMC, especially when recurrence occurred after a short
interval. The elevated serum thyroglobulin is not always
seen with metastasis [5]. Recurrences in remote organs
were rare, i.e., ﬁve in the lung, ﬁve in bone, one in the
mediastinum, and one in a miscellaneous site.
Discussion
This article is the largest report of papillary microcarci-
noma with long-term follow-up in the literature. The data
contained here may help guide diagnostic and therapeutic
algorithms for this increasingly common disease.
Difference from past reports
The differences of this article from our previous report [6]
are the proportion of patients with Graves’ disease (47.8%
in our previous report and 38.8% in this study), and the
proportion of patients with Hashimoto’s thyroiditis (2.1%
in the previous report and 8.8% in this report). One reason
for the discrepancy may be the use of ultrasonography with
increased identiﬁcation of these small tumors. Another
difference between the reports is the patient population
included. In this article only patients with pure papillary
carcinoma were included, whereas in our previous report a
small number of follicular carcinomas, cases of papillary
and follicular carcinomas in the same thyroid, and cases of
papillary and medullary carcinomas in the same thyroid
were included. In this report, the median follow-up period
was 15.1 years (mean = 16.5 years) and in our previous
report the median was 11 years.
Gender and risk of recurrence
In Japan, PMC is more prevalent in the female population.
In this series of patients, the male:female ratio was 1:9. In
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Fig. 8 Numbers of nodal metastases in recurrence-free survival rate.
Patients with a large number of nodal metastases had signiﬁcantly
worse recurrence-free survival than patients with fewer nodal
metastases
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Fig. 9 The interval between primary surgery and the ﬁrst recurrence.
Recurrence was seen in 73 patients (3.5%) over a 35-year period.
Among them, 68 patients experienced recurrence in the thyroid bed
and/or cervical lymph nodes. One patient had recurrence in the lung,
four patients in bone, and one patient in multiple sites. Median
interval between primary surgery and ﬁrst recurrence was 10.29 years.
The box represents the median quartile, the diamond represents the
average, and the bracket represents the short half
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Fig. 10 The interval between primary surgery and the second
recurrence. A second recurrence was seen in 12 patients (0.6%) over
a 35-year period. Four patients had recurrence in the lung, one patient
in bone, and one patient in the mediastinum. The box represents the
median quartile, the diamond represents the average, and the bracket
represents the short half
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123our previous report of small carcinoma of the thyroid,
including follicular carcinoma and medullary carcinoma,
the ratio was 1:8.4 [6]. This ﬁnding is not consistent with
the majority of autopsy studies that found no difference in
the prevalence of PMC across genders.
Age and risk of recurrence
Various risk group classiﬁcations regard age as one of the
most important factors for risk of recurrence [7]. By Cox’s
proportional hazard model, however, age is not a signiﬁ-
cant risk factor in this study. (Table 1). Chow et al. [8] also
found that age was not a signiﬁcant factor in predicting
disease recurrence or survival for PMC.
Size of PMC and risk of recurrence
When patients with primary tumors 5 mm or smaller are
compared with patients with primary tumors 6-10 mm, the
recurrence-free survival rate at 35 years is signiﬁcantly
better in the group with smaller tumors (Fig. 2). This
ﬁnding strongly suggests that even among PMC, larger
tumors have worse a prognosis compared to smaller ones.
In 2004, WHO revised the deﬁnition of T1 thyroid carci-
noma from 10 mm to 20 mm. This revision is in conﬂict
with the above ﬁnding if recurrence-free survival is con-
sidered an important outcome measure.
Autoimmunity
Vini et al. [9] reported that patients with Graves’ disease
have a better prognosis; however, reports from many sur-
geons could not reproduce the same results [10–14].
Patients with Hashimoto’s disease and PMC had a recur-
rence-free survival at 35 years that was better than those
preoperatively diagnosed with a benign nodule and PMC
[15]. Patients who were preoperatively diagnosed as having
any kind of diffuse goiter coexisting with their PMC had
recurrence-free survival at 35 years that was better than
those preoperatively diagnosed as having a benign nodule
and PMC (Fig. 4). When the size of the PMC is compared
among the above groups, the PMC of the Graves’ disease
group and the Hashimoto’s thyroiditis group had a maxi-
mum dimension of 3.9 ± 2.3 mm. The PMC of patients
with any type of diffuse goiter had a maximum dimension
of 4.9 ± 2.8 mm, and the mean size of the primary PMC
tumor of those preoperatively diagnosed with a combina-
tion of benign nodule and PMC was 7.4 ± 2.5 mm.
Therefore, the average size of the tumor could be one of the
factors in a better prognosis.
Nodal metastasis
Patients who had no gross metastases and those whose
metastases were not examined had almost the same
recurrence-free survival rate (Fig. 7). Cases in which gross
lymph node metastases were found had a substantially
worse prognosis. This may suggest that if an experienced
surgeon believes that lymph node removal is not indicated
because the nodes appear normal, then nodal metastases
probably is not present. Alternatively, it may be that central
neck nodal metastasis is relatively rare in patients with
tumors of this size, and so any deleterious effect is
diminished by the large number of node-negative patients
included in this group.
Recurrence and death
Tumor recurred in 73 patients (3.5%) over a 35-year time
span. Among them, 68 patients (90.7%) experienced
recurrences in the thyroid bed and/or cervical lymph nodes.
A few patients had up to four recurrences. Patients who had
recurrence in the neck area could be treated with secondary
surgery.
Death resulting from papillary thyroid carcinoma is
uncommon and is particularly rare in low-risk patients like
PMC [9]. Of 2070 patients who were followed up for
16.5 ± 7.3 years, only 12 patients (0.6%) died of thyroid
cancer.
Invasion
Invasion of the primary tumor beyond the thyroid capsule
is one of the prognostic risk factors of papillary cancer of
all sizes [6]. When the primary tumor adheres or invades
the recurrent nerve or the muscular layer of the esophagus,
the recurrence-free survival rate decreases signiﬁcantly
(Figs. 5 and 6).
Surgical treatment
For treatment of PMC we perform thyroid lobectomy alone
when there is no indication beyond the cancer therapy for a
bilateral procedure. When an adenoma is present in the
opposite lobe of the thyroid, we excise some benign thyroid
tissue. We do not perform total thyroidectomy or bilateral
thyroid lobectomy when PMC is limited to one lobe. When
lymph node metastasis is present in the lateral compart-
ment of the neck, modiﬁed radical neck dissection and
central compartment neck dissection is mandatory.
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In our previous report [6] we recommended TSH sup-
pression to all postoperative PMC patients, but the majority
of patients who did not have postoperative hypothyroidism
discontinued medication within a few years. We evaluated
whether patients who discontinued TSH suppression had a
higher incidence of recurrence. We found that there was no
statistically signiﬁcant difference. Because most patients
with one intact thyroid lobe have normal levels of T4, we
discontinued the practice of prescribing thyroid hormones
to postoperative patients with normal thyroid function.
Recently, it has been reported that TSH may not be the
dominant growth factor for benign and malignant thyroid
tumors [16]. This ﬁnding conﬁrms our observation. We do
not use radioactive iodine unless there is evidence of dis-
tant metastasis. In sum, our only postoperative
management is to observe the patient once a year with
ultrasonography and, if necessary, ﬁne-needle aspiration
cytology as well as checking serum thyroglobulin levels.
Pelizzo et al. [17] uses more aggressive treatments,
including total thyroidectomy and radioactive iodine
treatment. However, their recurrence rate is higher than
ours within a shorter follow-up period. There are many
experts who treat PMC with the same or slightly less
aggressive regimen as used for clinical papillary carcinoma
[18, 19]. Furlan et al. [20] use near total thyroidectomy and
optionally consider radioactive ablation. We consider thy-
roid lobectomy or subtotal thyroidectomy without
radioactive iodine ablation of residual thyroid tissue as
sufﬁcient therapy once unifocal PMC has been established.
Similarly, the Institute Gustave-Roussey group believe that
loboisthmectomy is the treatment of choice [21]. Peizzo
et al. [17] recommended lobectomy plus TSH suppression
in 1990. Rodriguez et al. [22] recommended lobectomy
alone. However, the treatment of incidental multifocal
PMC is still controversial. When other papillary micro-
carcinomas are found during surgery, the Institute Gustave-
Roussey group perform total thyroidectomy. However,
incidental PMC is often not proven until postoperative
histopathology is performed.
Conclusion
PMC is diagnosed more frequently because of high-quality
ultrasonography and ﬁne-needle aspiration cytology. In
2006, PMC represented more than half of papillary carci-
noma cases at our institution. Experienced physicians can
accurately biopsy PMC as small as 3 mm in diameter.
However, these results conﬁrm that papillary microcarci-
noma of the thyroid has an excellent prognosis. Lobectomy
may be sufﬁcient therapy in a vast majority of cases. TSH
suppression and radioactive iodine ablation of the
remaining thyroid tissue is not necessary. Rather, a higher
priority should be placed on follow-up with neck ultraso-
nography because 99.5% of recurrences ﬁrst appear in the
neck. To resolve clinical questions, ﬁne-needle aspiration
cytology can be repeated at regular intervals. Serum thy-
roglobulin levels can also be informative. The most
important lesson of our report is that recurrence can appear
even 30 years after primary surgery.
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